AstraZeneca PLC
AZN
$171.34
-$1.96-1.13%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.51B | 3.08B | 2.33B | 2.53B | 2.45B |
| Total Depreciation and Amortization | 1.58B | 1.37B | 1.17B | 1.55B | 1.39B |
| Total Amortization of Deferred Charges | -- | -- | 236.00M | -- | -- |
| Total Other Non-Cash Items | -788.00M | -87.00M | -189.00M | 217.00M | -108.00M |
| Change in Net Operating Assets | -438.00M | -1.00B | -1.20B | 835.00M | -345.00M |
| Cash from Operations | 2.87B | 3.36B | 2.34B | 5.13B | 3.39B |
| Capital Expenditure | -763.00M | -547.00M | -1.04B | -686.00M | -659.00M |
| Sale of Property, Plant, and Equipment | 4.00M | 8.00M | 3.00M | 0.00 | 9.00M |
| Cash Acquisitions | -33.00M | -257.00M | -273.00M | -328.00M | -267.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.12B | -996.00M | -140.00M | -987.00M | -1.19B |
| Cash from Investing | -2.91B | -1.79B | -1.45B | -2.00B | -2.11B |
| Total Debt Issued | -12.00M | 4.32B | -1.01B | -352.00M | 644.00M |
| Total Debt Repaid | -2.54B | -96.00M | -2.11B | -93.00M | -115.00M |
| Issuance of Common Stock | 6.00M | 10.00M | 23.00M | 5.00M | 4.00M |
| Repurchase of Common Stock | -46.00M | -612.00M | -13.00M | -19.00M | -3.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.00M | -3.29B | -- | -1.61B | -10.00M |
| Other Financing Activities | 0.00 | -72.00M | -294.00M | -3.00M | -2.00M |
| Cash from Financing | -2.59B | 267.00M | -3.28B | -2.07B | 518.00M |
| Foreign Exchange rate Adjustments | 9.00M | -18.00M | 4.00M | -12.00M | 29.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.63B | 1.82B | -2.38B | 1.05B | 1.83B |